Le Lézard
Classified in: Health
Subject: PDT

European doctors learn to access the heart from any approach with Baylis devices and expanded training program


Video Link: https://youtu.be/jS-sLqhQ5Fk

TORONTO, Nov. 21, 2017 /PRNewswire/ - Baylis Medical Company Inc. has launched a hands-on workshop in Europe that will train cardiologists on innovative tools that enable access to the heart from any approach. This includes a growing number of procedures that require physicians to use major veins that feed into the heart from above ? something the Baylis Medical SupraCross® RF System enables with ease.

Such alternate pathways offer a minimally invasive way to deliver life-saving treatments. Prior to the development of these tools, open heart surgery was the only option available for many high-risk patients.

Following its initial launch in Toronto, Canada, the SupraCross® Workshop has now expanded to Europe, a growing market for this one-of-a-kind technology. The program offers specialized training on the use of the Baylis Medical SupraCross RF System to interventional cardiologists ? specialized physicians who provide catheter-based treatment of various heart diseases.

"The SupraCross workshop was excellent," says Dr. Zachary Whinnett, a consultant cardiologist and electrophysiologist at Hammersmith Hospital, London UK, who participated in a recent Baylis training workshop in Amsterdam. "The superb hands-on experience with these advanced tools made superior access to the left atrium easy."

Baylis Medical's SupraCross RF System includes a steerable sheath and flexible radiofrequency wire that were designed to achieve controlled and precise transseptal access to the left side of the heart from any approach, including from above the heart. For example, these dedicated tools make it easier for physicians to place a pacemaker lead into the left heart in cases where traditional cardiac resynchronization therapy fails.

"These tools are also used for accessing the heart from the subclavian vein or internal jugular vein above the heart in cases where the lower femoral vein is blocked or does not otherwise have a continuous pathway to the heart," says Chris Bermingham, Team Leader, Clinical Education at Baylis. "This is a technically challenging procedure for even the most skilled physician, unless you have the right tools."

"Baylis is committed to developing innovative solutions that help all patients, particularly those for whom no other medical options are available," says Kris Shah, President of Baylis Medical. "That's why we developed the SupraCross system, and why we are expanding our specialized training program to Europe. We know the importance of offering best-in-class clinical support to physicians who must stay abreast of a constantly evolving medical field."

About Baylis Medical Company

Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while improving the lives of people around the world. The company has offices in Montreal and Toronto (Canada), Boston (U.S.), London (U.K.) and Munich (Germany). For more information, visit www.baylismedical.com

PRM-00273 EN J-1,2,3 V-1 © Copyright Baylis Medical Company Inc., 2017. Baylis Medical Company Inc. reserves the right to change specifications or to incorporate design changes without notice and without incurring any obligation relating to equipment previously manufactured or delivered. SupraCross and the Baylis Medical logo are trademarks and/or registered trademarks of Baylis Medical Company Inc.in the USA and/or other countries. Patents Pending and/or issued. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for U­­­se.

SOURCE Baylis Médical


These press releases may also interest you

at 08:16
Canadian health care providers now have access to clinical tools and resources they need to better support older adults experiencing...

at 08:15
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it will be attending the LSX World Congress (29-30 April) and presenting at Bio?quity Europe (12-14 May). The...

at 08:15
Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety...

at 08:15
Nuvation Bio Inc. , a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms....

at 08:15
Axiom Health, a leading provider of data analytics solutions for the medical device industry, today announced the appointments of Russell "Rusty" Lewis as Chief Executive Officer (CEO) and Jim Best as Chief Commercial Officer (CCO). These...

at 08:15
GlobeStar Therapeutics Corporation (GSTC), is a clinical stage pharmaceutical company focused on advancing new therapies for Multiple Sclerosis (MS) and other neurological diseases, including but not limited to Rheumatoid Arthritis (RA), released on...



News published on and distributed by: